0001643918 2025-05-01 2025-05-01 0001643918 dei:BusinessContactMember 2025-05-01 2025-05-01 iso4217:USD shares iso4217:USD shares true 2025-05-01 Non-accelerated Filer 0001643918 POS AM Biodexa Pharmaceuticals PLC X0 1 Caspian Point Caspian Way Cardiff CF10 4DQ +44 29 20480 180 Donald J. Puglisi 850 Library Ave. Suite 204 Newark DE 19711 302 738-6680 false This Post-Effective Amendment No. 1 (this “Post-Effective Amendment No. 1”) to the Registration Statement on Form F-1 (File No. 333-281489) (the “Registration Statement”) is being filed pursuant to our undertaking in the Registration Statement to update and supplement information contained in the Registration Statement, as originally filed on August 12, 2024, and declared effective by the Securities and Exchange Commission (the “SEC”) on August 19, 2024, as to incorporate by reference the Company’s Annual Report on Form 20-F for the year ended December 31, 2024, as filed with the SEC on April 11, 2025. The Registration Statement originally covered a resale (the “Offering”) by the selling shareholders identified in this prospectus, of up to an aggregate of 4,349,010,000 ordinary shares, nominal value £0.001 per share (the “Ordinary Shares”), of Biodexa Pharmaceuticals PLC, represented by 434,901 American Depositary Shares (the “Depositary Shares”) consisting of (i) 2,131,880,000 Ordinary Shares represented by 213,188 Depositary Shares issuable upon the exercise of Series J warrants, or Series J Warrants, issued in a July 2024 private placement, or the July 2024 Private Placement, (ii) 2,131,880,000 Ordinary Shares represented by 213,188 Depositary Shares, issuable upon the exercise of Series K warrants, or Series K Warrants, issued in the July 2024 Private Placement, and (iii) 85,250,000 Ordinary Shares represented by 8,525 Depositary Shares, issuable upon the exercise of placement agent warrants, or the July 2024 Placement Agent Warrants, issued in the July 2024 Private Placement.   The information included in this filing updates the Registration Statement and the prospectus contained therein.   No additional securities are being registered under this Post-Effective Amendment No. 1. Accordingly, this Post-Effective Amendment No. 1 concerns only the offer and sale of Ordinary Shares represented by Depositary Shares issuable from time to time upon exercise of such warrants that remain unexercised.   All applicable registration fees were paid at the time of the original filing of the Registration Statement.